Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Xiao Li1*, Martinus P. Stander2, Georges Van Kriekinge1 and Nadia Demarteau1

Abstract

Background: This study aims at evaluating the cost-effectiveness of a 2-dose schedule human papillomavirus (HPV) vaccination programme of HPV and human immunodeficiency virus (HIV) naïve 12-year-old girls, in addition to cervical cancer (CC) screening alone, in South Africa. The study aims to account for both the impact of the vaccine among girls who are HIV-positive (HIV+) as well as HIV-negative (HIV-) population.

Methods: A previously published Markov cohort model was adapted to assess the impact and cost-effectiveness of a HPV vaccination programme in girls aged 12 years (N = 527,900) using the AS04-adjuvanted HPV-16/18 vaccine from a public payer perspective. Two subpopulations were considered: HIV- and HIV+ women. Each population followed the HPV natural history with different transition probabilities. Model input data were obtained from the literature, local databases and Delphi panel. Costs and outcomes were discounted at 5%. Extensive sensitivity analyses were conducted to assess the robustness of the evaluation.

Results: Implementation of the AS04-adjuvanted HPV-16/18 vaccine in combination with current cytological screening in South African girls could prevent up to 8,869 CC cases and 5,436 CC deaths over the lifetime of a single cohort. Without discounting, this HPV vaccine is dominant over screening alone; with discounting, the incremental cost-effectiveness ratio is ZAR 81,978 (South African Rand) per quality-adjusted life years (QALY) gained. HPV vaccination can be considered cost-effective based on World Health Organization (WHO) recommended threshold (3 x gross domestic product/capita = ZAR 200,293). In a scenario with a hypothetical targeted vaccination in a HIV+ subpopulation alone, the modelled outcomes suggest that HPV vaccination is still cost-effective, although the incremental cost-effectiveness ratio increases to ZAR 102,479. Results were sensitive to discount rate, vaccine efficacy, HIV incidence and mortality rates, and HPV-related disease transition probabilities.

Conclusions: The AS04-adjuvanted HPV-16/18 vaccine can be considered cost-effective in a South African context although the cost-effectiveness is expected to be lower in the HIV+ subpopulation than in the overall female population. With improved access to HIV treatment, the HIV mortality and incidence rates are likely to be reduced, which could improve cost-effectiveness of the vaccination programme in South Africa.

Keywords: Cervical cancer, Vaccine, Human immunodeficiency virus, Human papillomavirus, South Africa, 2-dose, Cost-effective
Background

Human papillomavirus (HPV) is the necessary cause of cervical cancer (CC) [1], with an estimated 528,000 annual incident CC cases and 266,000 CC deaths worldwide in 2012 [2]. High-risk regions, with age-standardised incidence over 30/100,000 women, include Eastern Africa (42.7/100,000), Melanesia (33.3/100,000), Southern Africa (31.5/100,000) and Middle Africa (30.6/100,000) [2]. Most frequent HPV types found in CC are types HPV-16 and HPV-18 which account for approximately 70% of all cases worldwide [3, 4]. Many of the regions with high CC incidence, such as South Africa, are also burdened with high incidence of human immunodeficiency virus (HIV) infection [5, 6]. The high CC incidence could be partially related to the high HIV incidence. Individuals infected with HIV have an increased risk of HPV infection and the associated subsequent disease as a result of impaired immunity [7, 8]. A strong association between HIV-positive (HIV+) status and the prevalence of oncogenic HPV types, specifically HPV-16 and HPV-18, has been previously documented [7, 9, 10].

Three HPV vaccines are available throughout the world: the AS04-adjuvanted HPV-16/18 vaccine (Cervarix®, GSK), the HPV-6/11/16/18 vaccine (Gardasil®, Merck & Co., Inc.) and the HPV-6/11/16/18/31/33/45/52/58 vaccine (Gardasil 9, Merck & Co., Inc.). These vaccines can be used for the prevention of HPV-related diseases such as CC. Efficacy of these vaccines has been demonstrated in adolescents and adult women [11–15]. Moreover, HPV vaccines clinical trials in HIV-infected individuals have shown that these vaccines have clinically acceptable safety profiles and are immunogenic [16, 17].

Up to mid-2014, more than 50 countries worldwide introduced vaccination against HPV in their national immunisation programme for girls [18] including South Africa [19]. It has been reported that more countries are preparing to offer pre-adolescent girls HPV vaccination, including many African countries where a high HIV prevalence exists [20].

A systematic review on the cost-effectiveness, clinical impact and health economic impact of HPV vaccination concluded that routine vaccination of girls is cost-effective compared with CC screening alone [21]. One South African study reported an incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained of 1,078 US dollar (USD) from a health service perspective [22]. However, to our knowledge, no model explicitly has taken into account the specificity of a HPV infected subpopulation in South Africa. Given the specific epidemiology of HPV infection and associated disease among this specific population, accounting for these in health economic evaluations in countries with a high prevalence of HIV may influence the cost-effectiveness of the implementation of a HPV vaccination programme. Also of interest would be to assess the effect of current change in HIV treatment and epidemiology on the cost-effectiveness of the HPV vaccination.

This study aims to assess the cost-effectiveness from a public payer perspective of a 2-dose AS04-adjuvanted HPV-16/18 vaccination programme added to the current CC screening programme, compared with the current CC screening programme (Papanicolaou smear test; Pap) alone in South Africa accounting for both the impact of the vaccine among the HIV+ as well as the HIV-subpopulation.

Methods

Model description

A previously published lifetime Markov process cohort decision tree with a one year cycle length focusing on oncogenic HPV was adapted to account for both HIV+ and HIV- subpopulations [23]. The model consisted of a series of health states representing the natural history of HPV infection and CC (see Fig. 1 for details) as in the initial model. The initial model was however duplicated to reproduce HPV natural history in both the HIV+ and HIV- subpopulations. Subjects moved between different health states over annual cycles throughout the disease process, governed by transition probabilities specific for each health state. Throughout the model, a proportion of the population yearly acquired HIV at an age-specific incidence rate reported for South Africa hence moving to the HIV+ sub-model.

Population

A 12-year-old girls’ cohort entered the model and was followed over lifetime. It was assumed that this cohort was both HIV- and HPV-naive at the start of the simulation (i.e. mother-to-child HIV transmission was not included in the model). Based on 2011 mid-year population estimates in South Africa, a cohort of 527,900 girls aged 12 years was considered for this analysis [24].

Model input data and assumptions

Natural history related to oncogenic HPV

Different transition probabilities were applied to the HIV-positive and negative populations to account for the specificities of the acquisition and natural history of HPV infection in these two subpopulations, as documented by a recent systematic literature review [25]. Age-dependent HIV incidence was taken into account to estimate the proportion of the population moving from the HIV- to HIV+ over the lifetime of the cohort. The transition probabilities related to the natural history of oncogenic HPV among HIV- subpopulation remained unchanged compared with Suarez et al. [23]. Those related to HIV+ subpopulation were consolidated from the
findings of a targeted literature review via PubMed using search terms related to HPV, HIV, cervix and neoplasm. Articles published before February 2014 were retrieved and the abstracts and selected manuscripts were assessed by a single reviewer. When data for HIV+ subjects were unavailable in the literature, conservative assumptions were made (i.e. same cervical intraepithelial neoplasia [CIN] treatment success rate in HIV+ and HIV- subpopulation). See Additional file 1.

The model was calibrated on incidence and mortality of CC in the HIV- population in South Africa by adjusting the transition probability from persistent CIN2/3 to CC as this parameter could not be retrieved from the literature due to the lack of these data for ethical reasons. For the HIV+ population, we assumed a multiplication factor of 2 for this specific transition probability, based on a prospective cohort study conducted by Massad et al. on progression and regression rates for abnormal cervical cytology among HIV-infected women [26]. The study reported greater progression rate within 6 months after diagnosis among HIV+ women (14 % vs. 7 %). See Table 1 for details on all annual transition probabilities included in the model.

Country specific data
Parameters related to HPV and HIV disease-specific incidence, background mortality rate, disease management, including CC screening and treatment of precancerous lesions and cancer were adapted to the South African setting and retrieved from the literature, local databases or expert opinion (see Table 2).

Cervical cancer screening
South Africa CC screening guidelines recommend that each woman from the age of 30 should be screened every 10 years at no cost [27]. The start age for CC screening was set to 30 years of age and at a frequency of once every 3 years until 60 years of age, as the South Africa national guideline and World Health Organization (WHO) recommend this frequency as best case for CC prevention or when resources allow for it [27, 28]. A cytological screening (i.e., Papanicolaou smear test) was assumed and sensitivity for the detection of cervical abnormalities with this test was retrieved from a meta-analysis on this subject. See Table 2 for details.

Utilities
Utilities for precancerous lesions, CC and CC survivors in South Africa were not available from the literature. Disutility values used were therefore retrieved from published reports for other settings and assumed to be identical for HIV- and HIV+ subpopulations (see Table 3) [29–33]. Baseline utility values in the absence of HPV
disease for HIV- and HIV+ subpopulations were assumed to be 1 and 0.81, respectively [34].

Resource utilisation and disease-related costs

Only direct medical costs were considered in this analysis. In accordance with the South Africa Pharmacoeconomic Guidelines, direct non-healthcare-related costs and indirect costs associated with quality-of-life and productivity loss were not included [35].

A two-round Delphi panel with 8 South African experts in the field of gynaecologic oncology was conducted to collect medical management-related resource use for patients with HPV-related disease in South Africa. The overall resources used for the treatment of precancerous lesions and CC included the resources associated with general practitioner (GP)/specialist visits, diagnostic procedures, treatments and hospitalisations. The reference unit costs (year 2013) for each of these identified resources were obtained from the South Africa Uniform Patient Fee Schedule (UPFS) [35] or from the literature when not available in the database (see Additional file 2 for details). Weighted averages of resource use multiplied with unit costs were included as cost input data into the model (Table 4). All costs are expressed in South African Rand (ZAR). Cost data extracted from the literature and reported in international dollar were converted to same year ZAR values using the Power-Purchase-Parity (PPP) adjusted exchange rate between ZAR and USD for the value year in the publication [36, 37]. These estimated same year ZAR values were then inflation-adjusted to 2013 using the South African Consumer Price Index data [38].

Vaccine costs

The 2013 list price of the AS04-adjuvanted HPV-16/18 vaccine of ZAR 595.39 per dose was used as the cost of vaccine per dose [39]. The national tender price is likely to be lower than its listed price; however, the tender price is unknown. A 2-dose schedule was assumed following the recent approval of the 2-dose schedule in South Africa.

Vaccine effectiveness and coverage

A proxy vaccine effectiveness was used, based on the most recent data on the AS04-adjuvanted HPV-16/18 vaccine efficacy reported for each endpoint irrespective of the causative type in the lesion in the Total Vaccinated Cohort from the end-of-study results from the PATRICIA trial [15]. Reported vaccine efficacy was used as a proxy for effectiveness as follows: CIN1+ 50.3 % (95 % CI: 40.2–58.8 %; CIN1 health state in the model), CIN2+ 64.9 % (95 % CI: 52.7–74.2 %; CIN2/3 health

| Table 1 Natural history of oncogenic HPV in HIV- and HIV+ subpopulations input data |
|---------------------------------|-----------------|----------------|
| Natural history-related parameter | Annual probability | Source |
| HPV-Onc to CIN1 | 0.049 | Adjusted from [60] (0.15 after 36 months and 0.21 after 60 months) |
| HPV-Onc to CIN2/3 | 0 | Spontaneous progression from HPV-onc to CIN2/3 within 1 year; assumed to be 0 |
| HPV-Onc clearance to normal | 0.293–0.553 | [29, 60–62] |
| CIN1 to CIN2/3 | 0.091 | [61–63] |
| CIN2/3 to CIN1 | 0.227 | [61–63] |
| CIN2/3 to CIN1 | 0 | Spontaneous regression from CIN2/3 to CIN1 within 1 year; assumed to be 0; all patients cured going to no HPV |
| HIV- CIN2/3 to persistent CIN2/3 | 0.114 | [62, 63] |
| Persistent CIN2/3 to cervical cancer | | |
| Age 15: 0.00 % | Based on estimated CIN2/3 and reported cervical cancer progression rates |
| Age 35: 1.10 % | |
| Age 45: 2.52 % | |
| Age 60: 7.56 % | |
| Age 60: 15.12 % | |

*The model calibration led to 0.12 % yearly increase from 20 years of age to 35 years, 0.2 % yearly increase from 36 years of age to 45 years, 0.3 % yearly increase from 45 years of age to 55 years, and 0.4 % yearly increase from 60 years of age onwards.

CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; HPV, human papillomavirus; HPV-Onc, oncogenic HPV types; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV+ positive; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions
### Table 2: HPV and HIV Epidemiology and Disease Management Input Data

| Parameter | Annual Probability | HIV- subpopulation | Source | HIV+ subpopulation | Source |
|-----------|--------------------|---------------------|--------|--------------------|--------|
| **Mortality rate** |                     |                     |        |                    |        |
| General mortality rate |                     |                     |        |                    |        |
| Age 15: 0.09 % | [65] | Age 15: 0.10 % | [65] | | | |
| Age 30: 0.20 % | | Age 30: 4.62 % | | | | |
| Age 45: 0.51 % | | Age 45: 7.71 % | | | | |
| Age 60: 1.56 % | | Age 60: 29.72 % | | | | |
| Age 75: 5.31 % | | Age 75: 37.38 % | | | | |
| **HPV and HIV incidence** | | | | | |
| HIV incidence rate in women | | | | | |
| NA | | Age 15: 0.025 | [65] | | | |
| Age 30: 0.004 | | | | | |
| Age 45: 0.001 | | | | | |
| Age 60: 0.001 | | | | | |
| 65+ years: 0 | | | | | |
| Oncogenic HPV incidence | 0.041−0.390 | [59] | 0.110−1.000 | [59, 66] | |
| **Cervical cancer parameters** | | | | | |
| Cervical cancer mortality | 0.110 | [2] | 0.291 | [67] | |
| Cervical cancer cured | 0.151 | [2] | 0.027 | [67] | |
| **HPV screening-related parameters** | | | | | |
| Screening coverage | 13.6 % | [59] | 13.6 % | [59] | |
| Screening ages | 30–60 years | [63] | 30–60 years | [63] | |
| Screening frequency | Every 3 years | WHO [27, 28] | Every 3 years | WHO [27, 28] | |
| CIN1 detected | 0.58 | [68] | 0.58 | [68] | |
| CIN2/3 detected | 0.61 | [68] | 0.61 | [68] | |
| **HPV-related disease management** | | | | | |
| Proportion of women treated if CIN1 is detected | 0.50 | Assumption | 0.50 | Assumption | |
| CIN1 treatment success | 0.90 | Assumption | 0.90 | Assumption | |
| Proportion of women treated if CIN2/3 is detected | 1 | Assumption | 1 | Assumption | |
| CIN2/3 treatment success | 0.90 | Assumption | 0.90 | Assumption | |

**Source:** ASSA, Actuarial Society of South Africa; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV-positive; HPV, human papillomavirus; ICO, Institut Català d’Oncologia; Pap, Papanicolaou smear test

### Table 3: Utility Input Data [29–33]

| Health state | Disutility value | Utility value (HIV-); baseline value = 1 | Utility value (HIV+); baseline value = 0.81 |
|--------------|------------------|----------------------------------------|----------------------------------------|
| No HPV       | 0                | 1                                      | 0.81                                   |
| HPV-Onc      | 0                | 1                                      | 0.81                                   |
| CIN1         | 0                | 1                                      | 0.81                                   |
| CIN1 det     | 0.013            | 0.987                                  | 0.797                                  |
| CIN2/3       | 0                | 1                                      | 0.81                                   |
| CIN2/3 det   | 0.013            | 0.987                                  | 0.797                                  |
| Cervical cancer | 0.273        | 0.727                                  | 0.537                                  |
| Cervical cancer cured | 0.062       | 0.938                                  | 0.748                                  |

**Source:** ASSA, Actuarial Society of South Africa; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; det, detected; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV+ positive; HPV, human papillomavirus
state) and CIN3+ 93.2 % (95 % CI: 78.9–98.7 %; CC health state) [15]. Vaccine efficacy in HIV+ subjects is assumed to be the same as those reported for HIV- cohort in the PATRICIA trial, based on recently reported immunogenicity results from a phase I/II clinical trial in HIV+ women in South Africa showing the vaccine is immunogenic and does not impact on HIV disease progression in HIV+ women [16].

A vaccination schedule with 2 doses for the target age-group was assumed, as recommended by the WHO recently [40], and approved by the South African health authorities. Vaccine efficacy for the 2-dose schedule was assumed identical to the vaccine efficacy reported for a 3-dose schedule based on the result of recent immunogenicity studies demonstrating non-inferiority of a 2-dose vs. a 3-dose schedule [41–43]. In the base case analysis, we assume 100 % vaccination coverage (which does not impact the cost-effectiveness of the vaccine as the model used has a static design) and lifetime vaccine-induced protection in both HIV- and HIV+ subpopulations based on a mathematical modelling prediction [44].

Discounting
In accordance with South Africa Pharmacoeconomic Guidelines for economic evaluations, future costs and outcomes were discounted at a rate of 5 % [35].

Data availability
All input data were retrieved from publicly available sources and access to the ASSA2008 model was granted by the actuarial society of South Africa in 2012 and confirmed in 2015.

Model outcomes
Base case analysis
For the base case analysis, a 2-dose AS04-adjuvanted HPV-16/18 vaccine in combination with the current Pap smear screening programme, compared with the current Pap smear screening programme alone, was assessed. Discounted and undiscounted cost, health outcomes, incremental values and cost-effectiveness ratios were estimated.

According to the WHO recommendation for pharmacoeconomic evaluations, an intervention can be considered cost-effective when the ICER is below the threshold of 3 x gross domestic product (GDP) per capita [45] and highly cost-effective below 1 x GDP per capita. GDP per capita at current prices in South Africa was ZAR 66 764 in 2013 [36].

Scenario analyses
The cost-effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in a strictly hypothetical HIV+ population was specifically modelled as for the base case analysis. When assessing the HIV+ subpopulation, the HPV infection rate in the HIV- population was set to be 0, to restrict the estimation of HPV related burden in the HIV+ population. The vaccination cost was attributed to girls that would become HIV+ over their lifetime. The subject would acquire HIV according to the South African incident rate and would be included in the HIV+ subpopulation. This analysis corresponds to a sub-evaluation of girls of whom the future HIV status would be known at the time of vaccination. Discounted and undiscounted outcomes were investigated.

Sensitivity analysis
➢ Overall
To account for the uncertainty in model parameters, a one-way sensitivity analysis on the discounted ICER was performed, varying key parameters in the model by ±20 % (x0.8 – x1.2) from their baseline values where 95 % confidence interval (CI) was not available. For vaccine efficacy, the 95 % CI values were taken as minimum and maximum values (see Additional file 3).

➢ HIV+ subpopulation
Although the vaccine efficacy and duration of protection remains unknown in HIV+ subpopulation, we have evaluated the impact of changes by means of one-way sensitivity analysis on the discounted ICER, by varying the vaccine effectiveness and vaccine duration of protection using the following values:

- vaccine effectiveness: relative reduction of 5 % (x0.95) to 30 % (x0.70) with a 5 % increment of the base case value
- vaccine duration of protection: waning of immunity from 5 to 50 years after initial vaccination, followed by a booster dose for 40 % of the cohort at the time of waning.

➢ Vaccine price
A vaccine price sensitivity analysis on the discounted ICER varying the vaccine price with a range of 50 to 150 % of the list price per dose was performed.

### Table 4 Costs input data [36–38]

| Intervention                                      | Costs (ZAR) |
|--------------------------------------------------|-------------|
| Cost of regular screening negative Pap smear      | 256         |
| Regular screening + false positive               | 256 + 1 656 (assume 2 % false positive) |
| Treatment CIN1 detected                          | 830         |
| Treatment CIN2/3 detected                        | 2 464       |
| Cervical cancer stage I-IV                        | 40 507      |

CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; Pap, Papanicolaou smear test
Two-way sensitivity analysis
Impact of changes in HIV mortality and HIV incidence rate on the discounted ICER were evaluated using a two-way sensitivity analysis. The mortality was reduced by 10 % (×0.90) to 50 % (×0.50) and HIV incidence was varied by ±75 % (×0.25 – ×1.75). The HIV mortality under which the vaccine becomes highly cost-effective among the overall population was estimated by determining the reduction in HIV mortality under which the ICER reached 1 × GDP per capita (highly cost-effective).

Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was performed for both base case and scenario analyses using @Risk (Palisade Corporation, Ithaca, New York, USA) to test parameter uncertainty and to evaluate the overall robustness of the model. Distributions were assigned to transition probabilities, costs and utility using normal distribution (limited from 0 to 1 for probabilities) where confidence intervals were available, otherwise, uniform distribution was assigned ranging from 20 % above and below the base case value (see Additional file 4).
In total, 10,000 samples were generated from the assigned distribution.

**Results**

**Model validation**

The Markov cohort model adequately reproduced the age-dependent HIV prevalence rate, CC incidence and CC mortality rate for South Africa, as reported in Fig. 2. The modelled CC incidence and mortality rate in the HIV+ subpopulation was significantly higher compared with the HIV- subpopulation. This could however not be validated against observed data as these do not exist.

**Base case analyses**

Undiscounted and discounted costs and outcomes comparing CC screening in addition to HPV vaccination with CC screening alone for a single cohort of 12-year-old girls in South Africa are reported in Table 5. By implementing HPV vaccination, 8,869 (undiscounted) CC cases and 5,436 CC deaths (undiscounted) could be prevented over the lifetime of a single cohort of girls in South Africa. Total incremental undiscounted cost was ZAR −663,748,191 and 68,270 QALY were gained. The undiscounted results thus show that the HPV vaccination programme added to the current CC screening programme is dominant over the CC screening programme alone. Discounted results reported were ZAR 471,064,695 overall cost difference and 5,746 QALY gained, resulting in an ICER of 81,978 ZAR/QALY. Thus, HPV vaccination with the AS04-adjuvanted HPV-16/18 vaccine can be considered to be cost-effective according to the WHO recommendations [36, 45].

**Scenario analysis**

In the scenario analysis specific for the HIV+ subpopulation, a total of 1,813 CC cases (undiscounted) and 1,707 CC deaths (both undiscounted) could be prevented over the lifetime of the cohort. Total undiscounted cost difference with CC screening alone resulted in ZAR −46,418,189 and a QALY gain of 7,248 for a single cohort of girls aged 12 in South Africa, thus resulting in the HPV vaccination programme added to the current cervical screening programme to be dominant over the CC screening programme alone in a HIV+ subpopulation. Discounted at 5 %, results reported were ZAR 136,358,673 overall cost difference and 1,331 QALY gained, resulting in an ICER of 102,479. Thus, HPV vaccination with the AS04-adjuvanted HPV-16/18 vaccine can be considered to be cost-effective according to the WHO recommendations in this specific subpopulation [36, 45] (Table 6).

### Table 5 Base case results: overall 12-years-old girls cohort

| Outcomes               | Screening | Screening + HPV vaccination | Incremental value | ICER (ZAR/QALY) |
|------------------------|-----------|----------------------------|-------------------|-----------------|
| **NO DISCOUNTING**     |           |                            |                   |                 |
| Total costs            | ZAR 1,649,427,899 | ZAR 985,679,708           | ZAR −663,748,191  |                 |
| Vaccine cost           | ZAR 0     | ZAR 628,612,762            | ZAR 628,612,762   |                 |
| Screening cost         | ZAR 149,297,117 | ZAR 153,547,788            | ZAR 4,250,671    |                 |
| CIN1 treatment cost    | ZAR 10,577,161 | ZAR 3,746,430             | ZAR −6,830,731   |                 |
| CIN2/3 treatment cost  | ZAR 8,262,222 | ZAR 1,813,136              | ZAR −6,449,086   |                 |
| CC treatment cost      | ZAR 1,481,291,399 | ZAR 197,959,592          | ZAR −1,283,331,807 |                 |
| Life years             | 27,173,430 | 27,230,436                | 57,006           |                 |
| CC cases               | 10,244    | 1,376                     | −8,869           |                 |
| CC deaths              | 6,313     | 877                       | −5,436           |                 |
| QALYs                  | 26,554,764 | 26,623,034                | 68,270           | V + S dominant  |
| **DISCOUNTED AT 5 %**  |           |                            |                   |                 |
| Total costs            | ZAR 221,807,577 | ZAR 692,872,271       | ZAR 471,064,695  |                 |
| Vaccine cost           | ZAR 0     | ZAR 628,612,762            | ZAR 628,612,762  |                 |
| Screening cost         | ZAR 35,277,421 | ZAR 36,453,101           | ZAR 1,175,681    |                 |
| CIN1 treatment cost    | ZAR 2,775,840 | ZAR 1,007,252             | ZAR −1,768,588   |                 |
| CIN2/3 treatment cost  | ZAR 2,541,718 | ZAR 553,386              | ZAR −1,988,332   |                 |
| CC treatment cost      | ZAR 181,212,598 | ZAR 26,245,770          | ZAR −1,988,332   |                 |
| Life years             | 1,283,817  | 9,154,639                 | 4,633            |                 |
| QALYs                  | 8,904,494  | 8,910,240                 | 5,746            | ZAR 81,978      |

CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; QALYs, quality-adjusted life-years; ZAR, South African Rand; HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; V + S, HPV vaccination + screening
Sensitivity analyses

One-way sensitivity analyses on variation of key variables and the resulting ICER are reported in Fig. 3, showing that variation in the discount rate had the greatest impact on ICER estimates. For the overall population base case analysis (Fig. 3a), vaccine efficacy in HIV- subpopulation, HPV progression rate and vaccine efficacy in HIV+ subpopulation had a significant impact on the ICER. In the sensitivity analysis specific to the HIV+ subpopulation (Fig. 3b), main drivers of ICER estimates were HPV progression rate, vaccine efficacy and baseline utility in the HIV+ subpopulation.

In the overall population analysis, with 50 % increase in the vaccination price (Fig. 4a), results show that HPV vaccination is still cost-effective. When the vaccine price is reduced by 25 %, HPV vaccination becomes highly cost-effective in South Africa. In the HIV+ subpopulation analysis, the price range between highly cost-effective and cost-effective vaccination price is between ZAR 450 and 950 per vaccine dose respectively (Fig. 4b).

When the impact of vaccine efficacy (Fig. 5) on ICER estimates was assessed, results show that HPV vaccination remained cost-effective in the overall population when vaccine efficacy was reduced by 30 %. However, in the HIV+ subpopulation analysis, HPV vaccination became not cost-effective if vaccine efficacy was reduced by 25 %. A similar trend was observed for the impact on the duration of protection in the HIV+ subpopulation (Fig. 6) with the discounted ICER remaining below the cost-effectiveness threshold in the overall population but rapidly rose above the threshold if the duration of protection was shorter than 15 years in the HIV+ subpopulation.

The two-way sensitivity analysis reported in Table 7 demonstrates that with changes in HIV incidence (−75 to +75 %) and HIV mortality rate (from no change to −50 %) vaccination remained cost-effective or highly cost-effective in all scenarios in the overall population.

In the HIV+ subpopulation, a 22 % decrease in the HIV mortality rate, at current HIV incidence, lead to HPV vaccination becoming highly cost-effective (<1 × GDP per capita) (Fig. 7).

The results of the probabilistic sensitivity analysis are reported in the acceptability curve in (Fig. 8), which presents the cumulative probability in function of discounted ICER analysis. The probability of ICER being below the threshold (3 × GDP per capita) is 99 % for base case and 98 % for scenario. It shows that the scenario analysis has a slower slope towards the maximum indicating that the spread of the samples has a larger interval than for the base case. This may be due to

| Outcomes                  | Screening | Screening + HPV vaccination | Incremental value | ICER (ZAR/QALY) |
|---------------------------|-----------|----------------------------|------------------|-----------------|
| NO DISCOUNTING            |           |                            |                  |                 |
| Total costs               | ZAR 295 251 951 | ZAR 248 833 762 | ZAR −46 418 189 |                 |
| Vaccine cost              | ZAR 0     | ZAR 183 228 152           | ZAR 183 228 152  |                 |
| Screening cost            | ZAR 19 794 328 | ZAR 21 262 010           | ZAR 1 467 682    |                 |
| CIN1 treatment cost       | ZAR 3 641 306 | ZAR 557 658               | ZAR −3 083 648  |                 |
| CIN2/3 treatment cost     | ZAR 3 545 580 | ZAR 561 971               | ZAR −2 983 609  |                 |
| CC treatment cost         | ZAR 268 270 736 | ZAR 43 223 970           | ZAR −225 046 766 |                 |
| Life years                | 3 179 736  | 3 186 707                 | 6 971            |                 |
| CC cases                  | 2 161     | 348                       | −1 813           |                 |
| CC cancer deaths          | 2 035     | 328                       | −1 707           |                 |
| QALYs                     | 2 573 677 | 2 580 925                 | 7 248            | V + S dominant  |
| DISCOUNTED AT 5 %          |           |                            |                  |                 |
| Total costs               | ZAR 62 169 185 | ZAR 198 527 858 | ZAR 136 358 673 |                 |
| Vaccine cost              | ZAR 0     | ZAR 183 228 152           | ZAR 183 228 152  |                 |
| Screening cost            | ZAR 5 766 054 | ZAR 6 223 334           | ZAR 457 279     |                 |
| CIN1 treatment cost       | ZAR 1 126 206 | ZAR 177 452               | ZAR −948 755    |                 |
| CIN2/3 treatment cost     | ZAR 1 183 601 | ZAR 190 676               | ZAR −992 925    |                 |
| CC treatment cost         | ZAR 54 093 324 | ZAR 8 708 245           | ZAR −45 385 079 |                 |
| Life years                | 1 283 817  | 1 285 076                 | 1 259           |                 |
| QALYs                     | 1 039 522 | 1 040 852                 | 1 331           | ZAR 102 479     |

CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; QALYs, quality-adjusted life-years; ZAR, South African Rand; HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; V + S, HPV vaccination + screening

Table 6: Scenario results: HIV+ subpopulation
more parameters for the scenario analysis to have been subjected to uncertainty than for the base case.

The results indicate that even under parameter variation, HPV vaccination in South Africa is likely to be cost-effective in all target groups showing the important public health impact of vaccination in this setting.

**Discussion**

We evaluated the cost-effectiveness of a CC prevention programme in South Africa where HPV vaccination is added to the current CC screening programme. In this evaluation, we explicitly accounted for the existing HIV+ population in South Africa that have specific HPV-related disease history and hence a potential impact on the value of a HPV programme. To our knowledge, no analysis of this kind has been previously reported. The base case analysis (including 29% HIV+ and 71% HIV- over the lifetime of a single cohort of 12-year-old South African girls) showed that this strategy would be cost-effective when compared with CC screening alone. Similar conclusions have been previously reported in other settings although these analyses did not include HIV+ subpopulations [22, 23, 29, 46, 47].

Evidence exists demonstrating that the acquisition and progression of HPV is faster in HIV+ individuals making them more at risk of HPV-related cancers [7, 20, 48, 49].
Different transition probabilities were therefore applied to the HIV-positive and negative populations to account for the specificities of the acquisition and natural history of HPV infection in these two subpopulations, as documented by a recent systematic literature review [25]. Moreover, there is no sufficient evidence in the literature that HIV treatments have effect on the HPV natural history [50]. Vaccination would likely be the only way to effectively prevent the increased risk of HPV and HPV-related outcomes in a HIV+ population.

In this modelling exercise, HPV vaccination was considered for a cohort of HPV and HIV naïve South African 12-year-old girls. These girls may become HPV and/or HIV positive post vaccination. A specific scenario analysis on HIV+ population was conducted. This represents the population target at the age of vaccination as at that age we assumed no existing HIV infection. The modelled outcomes suggest that HPV vaccination remained cost-effective under the WHO recommended cost-effectiveness threshold in the overall population as well as in the HIV+ subpopulation, although the ICER (ZAR 102 479 per QALY gained) is higher than the one estimated for the overall population (ZAR 81 978 per QALY gained). Decrease in overall HIV-associated mortality rate for the HIV+ population would make HPV vaccination more attractive as more disease can be avoided in later life. Given current mortality rates in HIV+ women, most HIV+ women may die before they develop precancerous lesions, or indeed cancer, even when HPV disease develops faster in HIV+ individuals. With better access to HIV treatment in South Africa, HIV incidence and mortality rate is however likely to improve in the near future, and hence improve the cost-effectiveness of the vaccination programme. Results were most sensitive to variation of discount rate, vaccine efficacy, duration of vaccine-induced protection in the HIV+ subpopulation, HIV incidence and mortality rates and HPV vaccine price. The parameter with the largest impact on the ICER was the discount rate. A high discount rate favours disease preventive interventions that

![Fig. 4 One-way price sensitivity analysis](image-url)
are close to the time of disease onset. For CC specifically, a high discount rate disfavours HPV vaccination as CC take years or even decades to develop [51, 52]. A recent update of the National Institute for Health and Care Excellence (NICE) in the United Kingdom recommends a discount rate of 1.5% to be used in technological appraisals for diseases with an expected benefit leading to prevention of death or a benefit that is sustained for at least 30 years [53]. Applying this discount rate would favour prevention of disease and death further away in the future and improve cost-effectiveness for HPV vaccination substantially (results not shown).

A systematic literature review on the cost-effectiveness of HPV vaccination in middle and low income countries, including South Africa [54], found that most studies in these countries concluded that HPV vaccination is likely to be cost-effective or possibly even cost saving. An evaluation in the South African context specifically concluded that adding HPV vaccination can be considered highly cost-effective [22]. Our study estimated a higher ICER in the base case evaluation than the one reported in this previous evaluation (ZAR 102 479 ~ USD 10 609 vs. USD 1 078 per QALY gained) from a public payers perspective. Besides the inclusion of HIV-specific health
states in the current evaluation, the ICER difference between the two evaluations was driven by a lower 3% discount rate used in Sinanovic et al. evaluation compared with the 5% in the present evaluation. The Sinanovic et al. study was indeed published before the issue of the National Pharmacoeconomics Guideline mandating a 5% discount rate as baseline [35]. Cytological screening was used in both studies as screening strategy in South Africa. Sinanovic et al. used 3 times screening at 10-years interval starting at 30 years of age [22]. A screening with 3 years interval from age 30 to 60 years was used in this analysis, as recommended by WHO and the national guideline, if resources allow [27, 28]. A Pap test was assumed, an HPV DNA testing, with higher sensitivity and more automated process, may be recommended as triage testing or replace the current screening in the future which would also impact the results.

The treatment costs used in our study were based on a Delphi panel resulting in lower costs than included in the Sinanovic study which used updated costs from two earlier publications [37, 55]. Finally, the vaccine cost also differed. While the Sinanovic et al. study assumed vaccination cost of USD 570 including 3 doses and a booster rate of 50%, administration, wastage and vaccination programmatic costs, we however applied the vaccine price with the 2-dose schedule (ZAR 595.39 using listed price) based on the recent regulatory update.

Another population-level modelling study assessed the economic impact of the different CC prevention (screening and vaccination) in Sub-Saharan African countries. It demonstrated that HPV vaccination alone is highly cost-effective in South Africa when price per course is USD 100 (ICER = USD 4,900 per life year saved). The authors

**Fig. 6** Impact of duration of protection in HIV+ subpopulation: (a) overall population, (b) HIV+ subpopulation. BC, base case; CC, cervical cancer; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV+, HIV-positive; HIV-, HIV-negative; ICER, incremental cost-effectiveness ratio; ZAR, South African Rand.
also acknowledge the need of including HIV status in future modelling [56].

The tender price is likely to be lower than the listed price, which would further improve the cost-effectiveness of the vaccine compared with no vaccination. However, under variation of the vaccine price (from 50% decrease to 50% increase), HPV vaccination remained cost-effective. Therefore, higher vaccination costs including e.g. administration costs or wastage would still result in the vaccine to be cost-effective in South Africa. In this analysis, all scenarios used the cost of a 2-dose vaccination schedule, reducing the price of the vaccine, compared to 50% increase, HPV vaccination remained cost-effective. Therefore, higher vaccination costs including e.g. administration costs or wastage would still result in the vaccine to be cost-effective in South Africa. In this analysis, all scenarios used the cost of a 2-dose vaccination schedule, reducing the price of the vaccine, compared

| Incidence HIV+ mortality (base case) | HIV+ mortality−10% | HIV+ mortality−20% | HIV+ mortality−30% | HIV+ mortality−40% | HIV+ mortality−50% |
|-------------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| NO DISCOUNTING                      |                    |                    |                    |                    |                    |
| −75% V + S dominant                 | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| −50% V + S dominant                 | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| −25% V + S dominant                 | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| Base case                           | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| 25% V + S dominant                  | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| 50% V + S dominant                  | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| 75% V + S dominant                  | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     | V + S dominant     |
| DISCOUNTED AT 5%                     |                    |                    |                    |                    |                    |
| −75% 85 537                         | 84 256             | 82 724             | 80 862             | 78 551             | 75 609             |
| −50% 83 958                         | 81 600             | 78 845             | 75 590             | 71 693             | 66 948             |
| −25% 82 798                         | 79 513             | 75 754             | 71 421             | 66 383             | 60 466             |
| Base case                           | 81 978             | 77 880             | 73 275             | 68 080             | 62 189             |
| 25% 81 435                          | 76 610             | 71 279             | 65 375             | 58 824             | 51 540             |
| 50% 81 116                          | 75 635             | 69 667             | 63 167             | 56 089             | 48 385             |
| 75% 80 979                          | 74 896             | 68 362             | 61 352             | 53 842             | 45 817             |

The bold zone indicates the ICER is < 1 × GDP per capita (ZAR 66 764); V + S, HPV vaccination + screening.

Fig. 7 Sensitivity analyses: impact of HIV mortality rate in the HIV+ subpopulation. CC, cervical cancer; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV+, HIV-positive; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; ZAR, South African Rand.
with a 3-dose HPV vaccination schedule. Furthermore, using a 2-dose schedule may alleviate not only issues related to overall vaccination budget (also including e.g. administration, vaccine storage, transportation, ...) but additionally increase acceptability and hence compliance of the vaccine. These elements were not accounted for in this presented analysis [41].

Limitations of this analysis exist. The Markov model used here is a static model and therefore no dynamic effects such as herd protection were taken into account. Only the direct vaccine effect was considered which provides a conservative estimation of the effect of vaccination. Furthermore, adaptation of a dynamic model would require detailed inputs data for both HIV+ and HIV- population which would be very challenging to obtain and, hence, requiring many assumptions to be made which could drive the results of the analysis and add uncertainties. The use of a static model does also add transparency to both the analysis and data selection. The difference in HIV prevalence rate from age 20 to 45 between the model and the observed data (see Fig. 2) may be due to observed data being reported based on an annual cross-sectional population survey while the model follows a single age-cohort over lifetime based on today’s epidemiology and HIV treatment practice.

Most of the country-specific data in South Africa are reported at the population level (including both HIV+ and HIV- subpopulations). It is therefore very challenging to extract different parameters for either subpopulation from the reported data. Therefore, several conservative assumptions had to be made with regards to parameters for disease progression or CC mortality rate. Also, comparison with HIV+ specific CC incidence was not possible as such data are not reported anywhere. Furthermore, children born with HIV were not included in this analysis. Since the model follows HPV disease progression in both HIV-infected and uninfected population, this model implicitly assumes that HIV was acquired by sexual transmission.

Our analysis also did not address inequities in healthcare access that may exist in and between populations in South Africa. Access to CC screening may not be readily available for all women in South Africa leading to excess risk of this cancer in unscreened women [29]. HPV vaccination given to girls age 12 may, to a certain extent, improve access to prevention of CC for large groups in the population thereby creating more opportunities for individual development and generation of well-being. Moreover, there is not sufficient evidence that treatment of HIV has effect on HPV natural history in the literature; vaccination would likely be the only way to effectively alleviate the increased risk of HPV and HPV-related outcomes in HIV+ girls.

Although studies using mathematical simulation modelling cannot replace clinical trial-based evaluation, model-based analyses provide important information that can help prioritise and guide the implementation of healthcare choices in South Africa.

However, this analysis highlights that potential reduction in the future incidence of HIV in a population may impact the cost-effectiveness value of an HPV vaccine by lowering the ICER value. Also, this analysis highlights that reduction in HIV mortality, which can be expected with new treatments, would also improve the cost-effectiveness of the vaccination. This should be taken into account when implementing a vaccination programme among girls that for some will develop HIV
and hence could benefit more or benefit less of the programme depending on the future of HPV treatments or epidemiology.

Conclusions
Findings from this modelling exercise suggest that the introduction of the 2-dose AS04-adjuvanted HPV-16/18 vaccine in South Africa added to the current CC screening programme may lead to a strong reduction in the number of CC cases and related deaths in the HIV+ as well as the HIV- subpopulations and may be a cost-effective intervention in both the general overall female population and the HIV+ female subpopulation alike. Improvement in HIV treatment leading to better survival among the HIV+ further improved the cost-effectiveness of the implementation of a HPV vaccination programme in countries with high HIV prevalence such as South Africa.

Endnotes
'Cervarix®' is a registered trade mark of the GSK group of companies.

Additional files

- Additional file 1: Literature Review: natural history related to oncogenic HPV in HIV infected population in Africa or South Africa. (PDF 167 kb)
- Additional file 2: Resource use unit costs and cervical cancer treatment costs. (PDF 528 kb)
- Additional file 3: Input ranges for one way sensitivity analyses. (PDF 156 kb)
- Additional file 4: Multivariate probabilistic sensitivity analysis input data. (PDF 64 kb)

Abbreviations
ASSA: Actuarial Society of South Africa; BC: base case; CC: cervical cancer; CI: confidence interval; CN: cervical intraepithelial neoplasia; CN1: cervical intraepithelial neoplasia grade 1; CN2: cervical intraepithelial neoplasia grade 2 or 3; CPI: consumer price index; det: detected subjects with disease detected through screening; EX: exchange rate; GDP: gross domestic product; GP: general practitioner; HIV: human immunodeficiency; HIV+: human immunodeficiency virus-positive; HIV-: human immunodeficiency virus-negative; HPV: human papillomavirus; HPV-Onc: oncogenic HPV types; HSL: high-grade squamous intraepithelial lesions; ICER: incremental cost-effectiveness ratio; IEO: Institut Català d’Oncologia; IMF: International Monetary Fund; IFTS: International dollar; LSL: low-grade squamous intraepithelial lesions; NICE: National Institute for Health and Care Excellence; Pap: Papanicolaou smear test; Pop: population; PPP: purchasing power parity; QALY: quality-adjusted life years; UFFS: Uniform Patient Fee Schedule; USD: US dollar; V + S: vaccination plus screening; WHO: World Health Organization; ZAR: South African Rand.

Competing interests
GlaxoSmithKline Biologicals S.A. funded this research and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals S.A. also took in charge all costs associated with the development and publication of this manuscript.

MPS received personal fees from the GSK group of companies during the conduct of the study. XL, GVK and ND are employees of the GSK group of companies and ND reports restricted shares from the GSK group of companies.

Authors’ contributions
XL designed the health economic evaluation, developed and ran the model, acquired the input data, critically evaluated the review and assessed the robustness of results, and drafted and supplied critical revision to the manuscript; MPS designed the health economic evaluation, acquired the input data, critically reviewed the evaluation and assessed the robustness of results and supplied critical revisions to the manuscript; GVK designed the health economic evaluation, acquired the input data, critically evaluated the review and assessed the robustness of results, and supplied critical revisions to the manuscript; ND designed the health economic evaluation, critically evaluated the review and assessed the robustness of results, and supplied critical revisions to the manuscript. All authors had full access to the data and gave final approval before submission.

Acknowledgements
The authors would like to thank Sarah Fico (Business & Decision Life Sciences on behalf of GSK Vaccines) for publication co-ordination and editing support.

Author details
1Health Economics, GSK Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium.
2Health Economic Research, HEXOR (Pty) Ltd, Block J, Central Park, 400 16th Road, Midrand, Republic of South Africa.

Received: 20 January 2015 Accepted: 25 November 2015
Published online: 11 December 2015

References
1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–3.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. International Agency for Research on Cancer (IARC). France: Lyon; 2014.
3. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders P, Vracarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2003;366:991–8.
4. de Sanjosé S, Wijn GQ, Laia A, Daan TG, Jo EK, Belen L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.
5. Finnhuber C, Westreich D, Schulze D, Williams S, Siminyu M, Michelopoulou H, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc. 2012;15:17382.
6. Moodley J, Moodley K, Kleinsemsmidt I. Invasive cervical cancer and human immunodeficiency virus (HIV) infection: a South African perspective. Int J Gynecol Cancer. 2001;11:194–7.
7. Ahdieh L, Klein RS, Burki R, Cu-Uvin S, Schuman P, Duerr A, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2002;184:682–90.
8. Singh DK, Anastas K, Hoover DR, Burki RD, Shi Q, Ngendahayo L, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis. 2009;199:1851–61.
9. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Valles X, Ouedraogo A, Konate I, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer. 2006;95:355–62.
10. Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuchs PG, Pfister HJ, et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol. 2003;41:2763–7.
11. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazzano-Ponce E, Salmeron J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2212–27.
12. The Future II Study Group. Quadrivalent Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med. 2007;356:1915–27.
13. Pawsonen J, Naud P, Salmeron J, Weaver CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.
14. Kjaer SK, Sigurdsson K, Jersven ØE, Hernandez-Avilá M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2:968–78.

15. Lehtinen M, Paavonen J, Wheeler CM, Jaisaaman U, Garland SM, Castellocue X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.

16. Denny L, Hendricks B, Gordon C, Herve C, Thomas F, Hezareh M, et al. Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine In HPV-Positive Women In South Africa Up To 12 Months After Vaccination [abstract]. Rome, Italy: 2012 Figo World Congress of Gynecology & Obstetrics in Rome; 2012. p. 7–12. October 2012.

17. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57:75–44.

18. Weekly epidemiological record - 24 October 2014, 89th year http://www.who.int/ivberi/2014/04/32.pdf. Accessed: 17 Dec. 2014.

19. SA targets cervical cancer with HPV vaccine campaign 89th year http://www.southafrica.info/services/health/hpv-vaccine-130314.htm. Accessed: Sept. 2015.

20. HPV vaccination in populations with high HIV prevalence http://www.cervicalcanceraction.org/pubs/CCA_HPV_vaccine_HIV_prevalent_populations.pdf. Accessed: 4 Aug. 2014.

21. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72:715–43.

22. Sinanovic E, Moodley J, Barone MA, Wall S, Cleary S, Harnes J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009;27:196–202.

23. Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Tonvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2009;27:229–45.

24. Mid-year population estimates 2011 http://www.statssa.gov.za/publications/P0302/P0302011.pdf. Accessed: 2 Nov. 2012.

25. Lissouba P, van de Perre P, Aubert B. Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2013;89(3):250–6.

26. Massad LS, Ahiedie L, Benning L, Minkoff H, Greenblatt RM, Watts H, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women’s interagency HIV study. J Acquir Immun Defic Syndr. 2001;27:432–42.

27. National Department of Health, Women’s Health Research Unit University of Cape Town, Women’s Health Project University of Witwatersrand, and Engenderhealth: Implementing cervical screening in South Africa: Cervical health implementation project Volume I a guide for programme managers http://www.healthlink.org.za/uploads/files/CHIPvol1.pdf. Accessed: Sept. 2015.

28. World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. Geneva: World Health Organisation; 2006.

29. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.

30. Gold MR, Franks P, McCoy KJ, Fryback DG. Toward consistency in cost-effectiveness analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92.

31. Inserna R, Glass A, Ruth B. Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses [Abstract W-02]. In 22nd International Papillomavirus Conference & Clinical Workshop 2005, 30 April-08 May 2005. Vancouver, BC, Canada.

32. Myers JE, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analog scale versus time-trade-off elicitation [Abstract n° 542]. In Twenty-First International Papillomavirus Conference; 20-27 February 2004. México City, México.

33. Institute of Medicine (US) Committee to Study Priorities for Vaccine Development. Behavioural, economic, and societal harms associated with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. Cost Eff Resour Alloc. 2010;85.

34. Goldie SJ, Kuhn L, Lenny D, Pollack A, Wright TC, Bosch FX, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule. Results from a randomised study. Hum Vaccin. 2011;7:1374–86.

35. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353:2158–66.

36. South Africa Consumer Price Index (2008–2012) http://www.statssa.gov.za/publications/P0141/CPIHistory.pdf.

37. South African Medicine Price Registry http://www.mpr.gov.za/PublishedDocuments.aspx?DocId=21.

38. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89:465–91.

39. Lazzano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, et al. Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32:725–32.

40. Romanowski B, Schwartz TF, Ferguson LM, Peters K, Dionne M, Schulke Z, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin. 2011;7:1374–86.

41. Puthanakit T, Schwartz TF, Esposito S, Frenette L, McNeil S, Rheault P, et al. Immune response to a 2-dose schedule for the HPV-16/18 AS04-adjuvanted vaccine in girls (9–14) versus 3 doses in women (15–25): a randomised trial. 2013. (Abstract n° OC 6–11 presented at the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Congress, Florence, Italy, Nov. 3–6).

42. Aregay M, Shibly Z, Molenberghs G, David MP, Tibaldi F. Model-Based Estimates of Long-Term Persistence of Induced HPV Antibodies: A Flexible Subject-Specific Approach. J Biopharm Stat. 2013;23:1228–48.

43. World Health Organization: WHO guide for standardization of economic evaluations of immunization programmes: final version July 2008 http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.14_eng.pdf.

44. Berkof J, Boogaards JA, Denniel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013;31:471–9.

45. Marra F, Cloutier K, Oetgen B, Marra CA, Ogilvie G. Effectiveness and cost-effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics. 2009;27:127–47.

46. Nglandwe C, Love RJ, Richards PJ, House L, Wood C, Angellotta PC. The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia. Africa BMC Infect Dis. 2007;7:77.

47. Omar T, Schwartz S, Hannah C, Modinesyane T, Tshabangu N, Golub J, et al. Progression and regression of pre-malignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS. 2011;25:874–91.

48. Batcher LF, Sahasarabdudddh W. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer. 2010;58.

49. Berkof J, de Bruije NC, Zelinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer. 2005;115:268–75.

50. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152–64.

51. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. 2013. http://www.nice.org.uk/article/pg99/chapter/Foreword.

52. Fesemfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine. 2013;31:5786–96.

53. Goldie SJ, Kuhn L, Lenny D, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107–15.

54. Kim JJ, Campos NG, O'Shea M, Diaz M, Mutubayi A. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Vaccine. 2013;31 Suppl S6:70–72.
57. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van Wyk, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008: A Turning Tide Among Teenagers? Cape Town, South Africa: HSRC Press; 2009.
58. Incidence of histologically diagnosed cancer in South Africa, 2003, 2004 http://www.nioh.ac.za/?page=cancer_statistics&id=163. Accessed: 1 Feb. 2012
59. Institut Català d’Oncologia (ICO): Information Centre on HPV and Cancer (HPV Information Centre) http://www.hpvcentre.net/dataquery.php. Accessed: 10 Feb. 2014
60. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995–3002.
61. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Nat Cancer Inst. 2003;95:1336–43.
62. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35.
63. Hobowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252–8.
64. De Vuyst H, Lillo F, Brouet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545–54.
65. Actuarial Society of South Africa: ASSA2008: AIDS Demographic Model 2008 http://www.actuarialsocty.org.za/Societyactivities/CommitteeActivities/AidsCommittee/Models.aspx. Accessed granted in November 2012 and confirmed in November 2015 by the Actuarial Society of South Africa, owner of the model.
66. Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112:377–83.
67. Coghill AE, Newcomb PA, Madeleine MM, Richardson BA, Mutyaba I, Okuku F, et al. Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS. 2013;27(18):2933–42.
68. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit